Concentration of Risk

REGENERON PHARMACEUTICALS, INC.

Medium

REGN · Nasdaq · Pharmaceutical Preparations · CIK 0000872589

Latest filing: 10-K · 2026-02-04

Customer concentration

Significant Customers note · revenue dependency

High
Top exposure
50%
Customer A
Other major customers
Customer B27%
Each is a separate customer disclosed individually — the figures are not sub-parts of the headline and may be measured against different revenue bases, so they are not additive.
Flat

Click a point to open the SEC source

FY23FY24FY250%15%30%45%60%

Geographic concentration

Segment reporting · geographic revenue

Low
Top exposure
<10%
No disclosure detected
Flat

Supplier concentration

Risk Factors · supply chain dependency

Low
Dependency
Single-source, third-party
Single-source, third-party providersNamed
Qualitative disclosure — no % quantified (informational, not scored)
Flat
FY25

Qualitative dependency level by filing year.

Product concentration

ASC 275 · disclosed dependence on a specific product or service

Low
Top exposure
<10%
No disclosure detected
Flat

Credit concentration

ASC 825 · concentration of credit risk note

Medium
Receivables
28.1%
Sanofi Collaboration Agreement, Antibody
Flat

Click a point to open the SEC source

FY250%8%16%24%32%